Commitment to maximize the wealth of our shareholders and catering to the interests of our customers and employees.
Innovation to Nurture Good Partnerships with Customers
Develop therapies and processes and provide services of the highest value to nurture good partnerships with customers
Responsibility towards Environment, Safety and Health
Nurturing the undying spirit for researching active substances to combat disease, protect the environments we inhabit, and the Society we serve.
Commitment to the Highest Standards of Ethics & Integrity
Actions in accordance with words and values. Respecting the laws in business ethics of the countries in which we operate.
Valuing the Ability to Excel, Integrity, Knowledge, Skill, Diversity and Team work of Employees
Treat everyone fairly and with respect to create an environment of Mutual respect, encouragement and teamwork.
From Chairman's Desk
The Indian Pharmaceutical industry today is in the front rank of India’s science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organized sector, the Indian Pharma industry is estimated to be worth $20 billion, growing at about 8 to 9 percent annually by virtue of its quality producers and many units approved by regulatory authorities in USA and UK. The sector is highly fragmented with more than 20000 registered units and has expanded drastically in the last two decades. It is an extremely fragmented market with severe price competition and government price control and the leading 250 pharmaceutical company’s control 70% of the market with market leader holding nearly 7% of the market share.
Throughout the preceding itinerary, “Ind Swift”, whilst taking the strong initiatives to address emerging opportunities prevailing in this organized and high ranked industry, performed drastically; the extent of that sky-scraping growth, which your company has attained shall be justifiably perceptible if we glimpse at ORG/IMS statistics for the year 2004-05 when “Ind Swift” was ranked out at the 119th position in contrast to today when, cutting short that great gap, we are at No.35 among top 300 Pharma industries according to ORG/IMS. This amazing reflection could be observed by means of advanced international operations, marketing, Research & development and state-of-art manufacturing facilities.
Our domestic strategies include our robust hold in the major therapeutic segments viz. Diabtology, cardiovascular, anesthesiology and Oncology where we possess a substantial market share via introducing various new products. Apart from existing in multifarious segment, other extensive therapeutic segments in which we have achieved a good market share are Gynecology and pediatrics. Various new products have been planned to be launched in the upcoming phases through our 9 segment specific marketing divisions with 1500 strong field strength aiming to reach the maximum number of customers (over 3 lac doctors and same number of Chemists outlets) and strong distribution network to fulfill the market demand.
Another element of our domestic strategies is our state-of-the-art manufacturing facilities. After commissioning a cGMP/WHO unit in Baddi, we were successful in commissioning another one the same zone for soft gelatin encapsulation with an annual capacity of 36 crore. Upgradations as per WHO standards were also executed in the existing facilities at Parwanoo. Not only this, our GBU got MHRA & TGA approval.
Our Global strategies include our formulation business wherein the operations have been strengthened further with commercial launch of the company in Tanzania and Nigeria in Africa; Combodia, Myanmar, Vietman and Sri Lanka in Asia and by achieving tie ups with leading distributors for the France Phone countries, Ethiopia and Zambia in Africa; Yemen and UAE in ME; Moldova, Azerbaijan and Kazakhstan in CIS. A successful award of tenders in Sri Lanka was another highlight for our Global Business Unit. We have also increased focus on the Latin American operations in order to expedite start of commercial operations and to increase the potential of business.
We are optimistic that these initiatives in conjunction with our focused strategic direction will help us to grow 30-40% annually and subsequently increasing wealth in the hands of our valued shareholders.
Mr.S.R.Mehta (Chairman)
Infrastructure
Unique and unmatched excellence in pharmaceuticals manufacturing with highest reliance of product quality attributes is our corporate strength. Ind swift's multipurpose, multilocation manufacturing set-ups are spread across the lush-green plains of northern Indian states viz Himachal Pradesh, Haryana and Jammu and Kashmir. The locations are environmental pollution free and together offer approx. 5,00,000 sq. ft of newly constructed plants with state of the art facilities for manufacturing all types of dosage forms.
The facilities are built according to current guidelines of USFDA, MHRA, EU, and WHO, and accreditations with ISO 14000 series standard.
A strong and ever vigilant Quality Assurance System forms the backbone of our continuing compliance to stringent regulatory guidelines, backed by latest equipments and instrumentation system. We achieve constant compliance to product quality attributes with an enviable cost of efficiency. It is always our strong endeavor to continuously invest in newer products, process technologies and look out for new horizons in pharmaceutical business to establish our well earned leadership.
Research & Development
Ind Swift is known for it's reverse engineering ability with highly focused R & D capabilities (duly approved by Department of Science & Technology, Govt. of India) and is equipped with state-of-the-art equipment, facilities and talented pool of scientists and Researchers.
A well accepted expertise in NDDS, in India and the world over.
A US patent for Clarie OD, with a market size of US$ 300 million.
Another patent for Fexofenadine ODT with a market size of US$ 2.5 billion.
Development of 10 new molecules with a market size of US$ 6 billion.
Ind Swift's efforts and achievements in taste masking of macrolides was India's first and remains the only feat of its kind in the country. The R &D department is also involved in creating international opportunities and alliances for CRAMS business, contributing significantly to the Company's profitability. It also offers complete support to international partners for preparing and filing dossiers for finished dosages. By taking giant strides on roads less traveled, Ind-Swift has become one of India's fastest growing pharmaceutical companies.
HRD
In an industry where intellectual capital is the primary business driver, enhancing the quality of such intellect and retaining them over the years drives sustainable success.
We in the Ind Swift Group are of the strong belief that our employees are our greatest assets.
It is our endeavor to motivate and develop skills of every employee in a manner that leads to optimum utilization of Human Resources which subsequently results in the attainment of organization objectives.
An infectious spirit of co operation and mutual trust with an overall orientation towards the achievement of Total Customer Responsiveness has been induced among employees in Ind Swift Ltd. It is this spirit which forms the root of our work culture. To achieve such a high level of Motivation, Efficiency and Trust, we have been striving consistently by providing
A helpful and healthy warm organizational climate.
Maintaining a two way communication process, keeping the employees well informed on all matters relating to our company.
Providing Competitive salaries comparable to the best in the Industry.
Instilling a sense of teamwork and mutual trust.
Treating all employees as one and equal.
Encouraging employees to come up with suggestions for improving the quality of our services and attaining total customer delight.
We believe in an open door policy. All employees are free to take their problems to their immediate superiors who are readily available. All employees are also welcome to take any of their problems to Human Resource Department.
An atmosphere of openness and a sense of belonging prevails in the entire length and breadth of the Ind-Swift Group.There is a feeling of oneness and all are treated as equals.
Our Achievements
Sweet recognition has been one of our many rewards - this one being an intangible.
Ranked as one of the most promising pharmaceutical group in India by Express Pharma Pulse.
All India achievers award as legend in Business house category.
An ISO 9001, 2000 company.
Achieved Pharma Pulse award as fastest growing & most promising pharmaceutical company for three successive years.
Neyam International Supplier and exporter of alopathic medicines which includes safed musli, spirulina capsule, spirulina tablets, safed musli gymnema, sylvestre mudakathan leaf, coleus forskohlii and coleus roots.
Jishnu Pharmaceuticals Private Limited Engaged in manufacturing and supplying of antiseptic medical gel, medicated pain relief oil, antiseptic gel, pharmaceuticals pain relief oil and antiseptic gel cream.
Processing...
